Retrovirus-Mediated Transfection of the Tissue-type Plasminogen Activator Gene Results in Increased Thrombolysis of Blood Clots

  • Xianhua Wu
  • Yongsheng GongEmail author
  • Xuebing Ding
  • Gang Cheng
  • Weiya Yan
  • Xiaowei She
  • Changxing Wang
  • Xia Li
Original Article


Tissue-type plasminogen activator (tPA) is involved in the lysis of blood clots. In this study, we attempted to target thrombolysis and enhance blood clot lysis by generating a construct (pLEGFP-N1-tPA) to integrate tPA gene into the genome of different cell lines. pLEGFP-N1-tPA construct was generated and used to target the tPA gene in different cell lines. The thrombolytic effects mediated by the supernatant from transfected HeLa cells and Linx cells were assessed using plasma thrombus plates. Furthermore, enhanced green fluorescent protein (EGFP), which was fused to the tPA gene in the pLEGFP-N1-tPA construct, was analyzed under the fluorescent microscope to assess tPA localization. We also monitored tPA activity and expression in the transfected cell lines. As part of the study, we successfully generated the pLEGFP-N1-tPA construct. The sequence of this construct was verified and the construct was subsequently used to generate the PT67/pLEGFP-N1-tPA cell line. The pLEGFP-N1-tPA construct was also used to transfect HeLa cells and Linx cells. We observed that supernatants from transfected cells were capable of lysing thrombi. In addition, tPA activity and tPA concentration were elevated in the latter supernatants and tPA was rapidly and stably expressed in the transfected cell lines. These results reveal a potentially important thrombolytic role for tPA-targeted gene therapy following cardiac valve replacement.


Retroviridae tPA Heredity vector Thrombus Thrombolysis 



This study was funded by Natural Science Foundation of Jiangsu Province (grant number BK20141176). We thank Professor Xiangdong Fu (Department of Cellular and Molecular Medicine and Department of Pathology University of California, San Diego, La Jolla, CA, USA).


Funding was provided by Natural Science Foundation of Jiangsu Province (Grant No. BK20141176).

Compliance with ethical standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. Aloni PD et al (2016) Effect of Fagonia arabica on thrombin induced release of t-PA and complex of PAI-1 tPA in cultured HUVE cells. J Tradition Complement Med 6:219–223. CrossRefGoogle Scholar
  2. Ari H, Dogan A, Ceviker K, Aksoy F, Arslan A, Varol E (2015) A case series of obstructive prosthetic mitral valve thrombosis, successfully treated with low-dose, slow infusion tissue-type plasminogen activator. J Heart Valve Dis 24:353–359PubMedGoogle Scholar
  3. Bierhuizen MF, Westerman Y, Visser TP, Dimjati W, Wognum AW, Wagemaker G (1997) Enhanced green fluorescent protein as selectable marker of retroviral-mediated gene transfer in immature hematopoietic bone marrow cells. Blood 90:3304–3315PubMedGoogle Scholar
  4. Condro MC et al (2016) High-resolution characterization of a PACAP-EGFP transgenic mouse model for mapping PACAP-expressing neurons. J Comp Neurol 524:3827–3848. CrossRefPubMedPubMedCentralGoogle Scholar
  5. Eton D, Yu H, Wang Y, Raines J, Striker G, Livingstone A (2004) Endograft technology: a delivery vehicle for intravascular gene therapy. J Vasc Surg 39:1066–1073. CrossRefPubMedGoogle Scholar
  6. Everson EM, Trobridge GD (2016) Retroviral vector interactions with hematopoietic cells. Curr Opin Virol 21:41–46. CrossRefPubMedPubMedCentralGoogle Scholar
  7. Fernandes D, Umasankar U (2016) Improving door to needle time in patients for thrombolysis. BMJ Qual Improv Rep. CrossRefPubMedPubMedCentralGoogle Scholar
  8. Ghanta RK, Kron IL (2016) Patient-prosthesis mismatch: surgical aortic valve replacement versus transcatheter aortic valve replacement in high risk patients with aortic stenosis. J Thorac Dis 8:E1441–e1443. CrossRefPubMedPubMedCentralGoogle Scholar
  9. Gong Y, Wang F, Li X, Gao Z, Zhang K, Fan C, Liu X (2010) Tissue-type plasminogen activator gene targets thrombolysis in atriums. J Thromb Thrombolysis 30:507–514. CrossRefPubMedGoogle Scholar
  10. Gong YS, Zhang KL, Jiang XG, Wang ZW, Sun ZQ, Cai J (2007) Retroviral gene transfer of tissue-type plasminogen activator targets thrombolysis in vitro and in vivo. Gene Ther 14:1537–1542. CrossRefPubMedGoogle Scholar
  11. Guglielmetti LC et al (2016) Bridging anticoagulation after mechanical aortic heart valve replacement: a questionable routine. Ann Thorac Surg 102:48–54. CrossRefPubMedGoogle Scholar
  12. Halldorsdottir H, Nordstrom J, Brattstrom O, Sennstrom MM, Sartipy U, Mattsson E (2016) Early postpartum mitral valve thrombosis requiring extra corporeal membrane oxygenation before successful valve replacement. Int J Obstet Anesth 26:75–78. CrossRefPubMedGoogle Scholar
  13. Hussain M et al (2016) Systematic review and pooled analyses of recent neurointerventional randomized controlled trials: setting a new standard of care for acute ischemic stroke treatment after 20 years. Interv Neurol 5:39–50. CrossRefPubMedPubMedCentralGoogle Scholar
  14. Isotani A, Yamagata K, Okabe M, Ikawa M (2016) Generation of Hprt-disrupted rat through mouse←rat ES chimeras. Sci Rep 6:24215. CrossRefPubMedPubMedCentralGoogle Scholar
  15. Ji S et al (2011) Study on construction of nano tPA plasmid to prevent thrombosis after mechanical valve replacement in dogs. J Surg Res 168:e1–5. CrossRefPubMedGoogle Scholar
  16. Liappas G et al (2016) Nebivolol, a beta1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis. Oncotarget 7:30133–30146. CrossRefPubMedPubMedCentralGoogle Scholar
  17. Mohanlal R, Qiu Y, Zheng M, Mirkou A, Sridharan K, Keir C (2016) Long-term safety follow-up of subjects previously treated with non-replicating retroviral vector-based gene therapies. Molec Diagn Ther 20:591–602. CrossRefGoogle Scholar
  18. Nucifora G et al (2017) Changes of left ventricular mechanics after trans-catheter aortic valve implantation and surgical aortic valve replacement for severe aortic stenosis: a tissue-tracking cardiac magnetic resonance study. Int J Cardiol 228:184–190. CrossRefPubMedGoogle Scholar
  19. Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual. Cold Spring Harbor Lab, New YorkGoogle Scholar
  20. Tadayon A, Jamshidi R, Esmaeili A (2015) Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases. Int J Pharm 495:428–438. CrossRefPubMedGoogle Scholar
  21. Tan J, Aysenne A, Singh V (2017) Thrombolysis in real time: demonstration of revascularization with intravenous thrombolysis therapy in the CT scanner. J Neuroimag 27:50–58. CrossRefGoogle Scholar
  22. Tan T, Hu ZQ (2013) Construction and expression of retroviral vector pLEGFP-N1-TERT in preparation of seed cells for skin tissue engineering. Asian Pacific J Trop Med 6:960–963. CrossRefGoogle Scholar
  23. van Overbeek EC, Staals J, Knottnerus IL, ten Cate H, van Oostenbrugge RJ (2016) Plasma tPA-activity and progression of cerebral white matter hyperintensities in lacunar stroke patients. PloS ONE 11:e0150740. CrossRefPubMedPubMedCentralGoogle Scholar
  24. Wang W, Sun X, Lu L, Zheng JB, Tian Y, Wang W (2013) Cytotoxicity of lymphocytes activated by superantigen toxic-shock-syndrome toxin-1 against colorectal cancer LoVo cells. Molec Cellular Biochem 376:1–9. CrossRefGoogle Scholar
  25. Ziu E, Haley O, Ibrahimi M, Langan S, Simon S (2016) A series of cerebral venous sinus thromboses treated with intra-arterial tPA infused over ten hours with a 0.027-inch catheter and literature review. Cureus 8:e654. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Thoracic-Cardiovascular SurgerySuzhou Municipal Hospital, Nanjing Medical UniversitySuzhouPeople’s Republic of China
  2. 2.Department of NephrologySuzhou Municipal Hospital, Nanjing Medical UniversitySuzhouPeople’s Republic of China

Personalised recommendations